Publications
104
Citations
1,384
Est. group size
~18
Recurring co-author estimate
Active years
32
Publishing since 1995
Paul Monk's research centers on clinical trials for genitourinary cancers, especially metastatic castration-resistant prostate cancer, testing new drug combinations such as immune activators, hormone-pathway inhibitors, and immunotherapies. His work also extends to bladder and kidney cancer treatment studies, largely through multi-site phase I-III clinical trials. This work is aimed at evaluating new and combination therapies to improve outcomes for patients with advanced prostate and other urologic cancers.
Publication output has fluctuated over the past decade but shows an overall increase, with output rising notably in 2024 and 2025 compared to earlier years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology · 2025
- Overall survival in metastatic castration-resistant prostate cancer (mCRPC): A retrospective electronic medical record analysis of men treated with sipuleucel-T in community urology over 14 years.
Journal of Clinical Oncology · 2025
- Metastatic Castration-Resistant Prostate Cancer: 14-Year Real-World Sipuleucel-T Outcomes in Urology
Research Square · 2025
- PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
Journal of Clinical Oncology · 2024
- Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Clinical Cancer Research · 2024
- Data from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
2024
- Supplementary Table S2 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
2024
- Supplementary Figure S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
2024
- Supplementary Table S3 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
2024
- Supplementary Table S3 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
2024
- Data from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
2024
- Supplementary Figure S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
2024
- Supplementary Table S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
2024
- Supplementary Table S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
2024
- Supplementary Table S2 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
2024
- Journal of Clinical Oncology×47
- Annals of Oncology×6
- Journal of the National Comprehensive Cancer Network×2
- Cancer Medicine×2
- Cancer Research×2
- Edmund Folefac
Medicine · The Ohio State University
- Timothy D. Gauntner
Medicine · The Ohio State University
- Xiangnan Guan
Medicine · The Ohio State University
- Dinuka De Silva
Medicine · Indiana University
- Thomas A. Gardner
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile